+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 21Years +
All Genders
ID07874503

Evaluation of Safety and Preliminary Effectiveness of Endo-Tek Hydrogel Cell Graft for Corneal Endothelial Dysfunction

Led by OcuCell · Updated on 2026-10-15

30

Participants Needed

1

Research Sites

2 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and feasibility of using Endo-Tek, a cultivated allogeneic corneal endothelial cell graft attached to a hydrogel substrate, to treat corneal endothelial cell dysfunction. This Phase 1 study aims to assess treatment-emergent and serious adverse events up to 24 weeks after transplantation. The study also investigates preliminary effectiveness by comparing vision quality, corneal thickness, and corneal cell density before and after surgery. Participants receive the Endo-Tek graft as a treatment during a surgical procedure. The study is designed as a single-group intervention where all enrolled participants undergo this treatment. After transplantation, participants are monitored for safety and changes in vision and corneal health over a 24-week period. Throughout the study, participants must attend follow-up visits to assess visual acuity, corneal thickness, and endothelial cell density, as well as monitor any adverse events related to the treatment. The total duration for safety assessment post-transplantation is 24 weeks, during which researchers gather data to evaluate the treatments safety and preliminary efficacy in this eye condition.

CONDITIONS

Brief Title

Safety and Efficacy of Cultivated Allogeneic Corneal Endothelial Cells Attached to a Hydrogel Substrate (Endo-Tek™) as a Treatment for Corneal Endothelial Cell Dysfunction

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here